Genprex Strengthens Senior Team and Continues to Advance Operations
February 27 2019 - 8:30AM
Business Wire
Company is Establishing Growth, Solidifying
Manufacturing and Supply Chain and Focusing on Strategic
Communications in New Year
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy
company developing a new approach to treating cancer based upon a
novel proprietary technology platform announced that it is
continuing to grow its senior team with the hiring of Eric
Chapdelaine, Senior Director of Pharmaceutical Sciences and
Manufacturing, and Kalyn Dabbs, Senior Manager of Communications
and Marketing, effective immediately. These hirings reflect the
company’s latest steps in preparing to grow its operations and
place an increased emphasis on corporate communications in
2019.
As the Senior Director of Pharmaceutical Sciences and
Manufacturing, Eric Chapdelaine will oversee the company’s
analytical development, chemistry, manufacturing and controls,
technical operations and supply chain management for Genprex. He
brings with him 14 years of experience in the pharmaceutical and
biotech industries with a proven track record of driving growth. In
his most recent role as the Director of Quality Control and
Analytical Development at Cognate BioServices, he oversaw a staff
of more than 40 employees in multiple laboratories working on cell
and gene therapy. As the Senior Manager of Communications and
Marketing, Kalyn Dabbs will be responsible for developing and
implementing internal and external communication and marketing
plans and managing the company’s digital strategy, an initiative
the company has previously indicated will be a corporate focus in
2019. Prior to joining Genprex, Dabbs spent the past six years
working in various communications and marketing roles in the
healthcare and wellness industries.
“Having Eric and Kalyn join the Genprex team will bring value to
the company and enhance our growth and communication efforts,” said
Rodney Varner, Genprex’s Chief Executive Officer and Chairman.
“Eric’s experience at both biotech companies and contract
development and manufacturing organizations will be invaluable in
managing and coordinating manufacturing partners and scale-up
activities as we expand our research and development efforts and
clinical trials of our lead product candidate, Oncoprex™, at the
University of Texas MD Anderson Cancer Center and potentially other
clinical sites.”
“Kalyn's role with our company will be essential as we execute
our shareholder outreach and communications strategy in the coming
year,” Varner continued. “We recognize the importance of boosting
awareness of Genprex’s unique approach to cancer treatment, and
Kalyn will help enable us to increase the quality and quantity of
our corporate communications.”
The new hires are just the latest high-profile additions to the
Genprex team in the past few months. Eric and Kalyn join Jan
Stephens, RN, who came onto the team at the end of October as
Genprex’s Vice President of Clinical Operations to oversee the
company’s clinical operations as it expands its clinical trials of
Oncoprex.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
Genprex’s growth and expansion of its operations, including
expansion of its clinical trials, and the effects of Oncoprex on
cancer. Risks and uncertainties associated with Genprex and its
lead product candidate Oncoprex are described more fully under the
caption "Risk Factors" and elsewhere in our filings and reports
with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190227005138/en/
Genprex, Inc.(877) 774-GNPX (4679)
Investor RelationsGNPX investor relations(877) 774-GNPX
(4679) ext. #2investors@genprex.com
Media ContactGenprex Media Relations(877) 774-GNPX (4679)
ext. #3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024